Clinical Trial Update: Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Z-521 (oral sodium phosphate) for treatment of primary hypophosphatemic rickets has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatemic Rickets Primary

Drugs mentioned

• Z-521 (Oral Sodium Phosphate) (sodium phosphate)

Snippet

Sponsor: Zeria Pharmaceutical | Conditions: Primary Hypophosphatemic Rickets | Phase 3 | Status: COMPLETED